SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)

Michael L. Curtin(AbbVie (United States)), Michael R. Michaelides(AbbVie (United States)), Peter Kovar(AbbVie (United States)), Bryan K. Sorensen(AbbVie (United States)), Anil Vasudevan(College of Medicine & JNM Hospital), Chris Tse(AbbVie (United States)), Terkel Hansen(AbbVie (United States)), Ramzi F. Sweis(AbbVie (United States)), Ana L. Aguirre(AbbVie (United States)), Robin R. Frey(AbbVie (United States)), Richard F. Clark(UC San Diego Health System), Fritz G. Buchanan(AbbVie (United States)), Noah P. Tu(AbbVie (United States)), Dong Cheng(AbbVie (United States)), Marina Pliushchev(AbbVie (United States)), Anurupa Shrestha(AbbVie (United States)), Julie L. Wilsbacher(AbbVie (United States)), Violeta L. Marin(AbbVie (United States)), David Maag(AbbVie (United States)), Kevin R. Woller, Nirupama B. Soni(AbbVie (United States)), H. Robin Heyman(AbbVie (United States)), Gary G. Chiang(Therapeutics Clinical Research), Jun Guo(AbbVie (United States)), Ilaria Badagnani(AbbVie (United States)), Kenton L. Longenecker(AbbVie (United States)), Min Cheng, Paul L. Richardson, Kathy Sarris(AbbVie (United States)), Diana Raich(AbbVie (United States)), Alla Korepanova(AbbVie (United States)), George Doherty, Mikkel A. Algire(AbbVie (United States))
Bioorganic & Medicinal Chemistry Letters
June 14, 2017
Cited by 21


Related Papers